EPINEPHRINE DELIVERY DEVICE

Illinois General Assembly - Full Text of HB3454

Select Language

×

The Illinois General Assembly offers the Google Translate™ service for visitor convenience. In no way should it be considered accurate as to the translation of any content herein.

Visitors of the Illinois General Assembly website are encouraged to use other translation services available on the internet.

The English language version is always the official and authoritative version of this website.

NOTE: To return to the original English language version, select the "Show Original" button on the Google Translate™ menu bar at the top of the window.

Choose Language

English

Afrikaans

Albanian

Arabic

Armenian

Azerbaijani

Basque

Bengali

Bosnian

Catalan

Croatian

Czech

Danish

Dutch

Esperanto

Estonian

Filipino

Finnish

French

Galician

Georgian

German

Greek

Gujarati

Haitian Creole

Hausa

Hawaiian

Hebrew

Hindi

Hungarian

Icelandic

Indonesian

Interlingua

Interlingue

Inuktitut

Irish

Italian

Japanese

Javanese

Kannada

Khmer

Korean

Latin

Latvian

Lithuanian

Luxembourgish

Macedonian

Malagasy

Malayalam

Maltese

Maori

Marathi

Myanmar

Nepali

Norwegian

Odia

Pashto

Punjabi

Romanian

Russian

Samoan

Sango

Sanskrit

Sardinian

Sindhi

Sinhala

Slovak

Slovenian

Somali

Southern Sotho

Spanish

Sundanese

Swahili

Swedish

Tamil

Telugu

Thai

Tigrinya

Tonga

Turkish

Ukrainian

Urdu

Vietnamese

Welsh

Xhosa

Yiddish

Yoruba

Zulu

Powered by
Translate

Close

Illinois General Assembly

Top Navigation Bar

Translate

Learn

Select General Assembly

Search the 104th General Assembly

Enter search terms for legislation, members, committees, or schedules.

ILGA.GOV

LEGISLATION & LAWS

Bills & Resolutions

Public Acts

Illinois Compiled Statutes

Illinois Constitution

Search Legislation

Glossary

Guide

Reports & Inquiry

Legislative Reports

Special Reports

FTP Site

Legislator Lookup

Capitol Complex Phone Numbers

Rules & Regulations

Illinois Register

Administrative Rules

Senate

Members

Schedules

Committees

Request for Remote Testimony

Journals

Transcripts

Rules

Audio/Video

FOIA Information

Senate Employment Opportunities

Media Guidelines

House

Members

Schedules

Committees

Submit testimony for House Committees

Journals

Transcripts

Rules

Audio/Video

FOIA Information

House Employment Opportunities

Log In

Mobile Top Bar

Search the 104th General Assembly

Enter keywords to search the Illinois General Assembly website.

Full Text of HB3454

Home

Legislation

Full Text

HB3454 - 104th General Assembly

Bill Status

Full Text

Votes

Witness Slips

Select Menu

Bill Status

Full Text

Votes

Witness Slips

Printer Friendly Version

Introduced

Engrossed

Enrolled

Senate Amendment 001

Senate Amendment 002

Printer Friendly Version

Introduced

Engrossed

Enrolled

Senate Amendment 001

Senate Amendment 002

Open PDF

HB3454 Enrolled
LRB104 09749 BDA 19815 b
1

AN ACT concerning health.

2

Be it enacted by the People of the State of Illinois,
3
represented in the General Assembly:

4

Section 5.
The Illinois State Police Act is amended by
5
changing Section 40 as follows:

6

(20 ILCS 2610/40)
7

Sec. 40.
Administration of epinephrine.
8

(a) This Section, along with Section 10.19 of the Illinois
9
Police Training Act, may be referred to as the Annie LeGere
10
Law.
11

(b) For the purposes of this Section,
"epinephrine
12
delivery system"

"epinephrine auto-injector"
means a
13
single-use device used for the automatic injection of a
14
pre-measured dose of epinephrine into the human body
15
prescribed in the name of the Illinois State Police.
16

(c) The Illinois State Police may conduct or approve a
17
training program for State Police officers to recognize and
18
respond to anaphylaxis, including, but not limited to:
19

(1) how to recognize symptoms of an allergic reaction;
20

(2) how to respond to an emergency involving an
21

allergic reaction;
22

(3) how to administer an
epinephrine delivery system

23

epinephrine auto-injector
;

HB3454 Enrolled
- 2 -
LRB104 09749 BDA 19815 b
1

(4) how to respond to an individual with a known
2

allergy as well as an individual with a previously unknown
3

allergy;
4

(5) a test demonstrating competency of the knowledge
5

required to recognize anaphylaxis and administer an
6

epinephrine delivery system

epinephrine auto-injector
; and
7

(6) other criteria as determined in rules adopted by
8

the Illinois State Police.
9

(d) The Illinois State Police may authorize a State Police
10
officer who has completed the training program under
11
subsection (c) to carry, administer, or assist with the
12
administration of
epinephrine delivery systems

epinephrine
13
auto-injectors
whenever he or she is performing official
14
duties.
15

(e) The Illinois State Police must establish a written
16
policy to control the acquisition, storage, transportation,
17
administration, and disposal of
epinephrine delivery systems

18
epinephrine auto-injectors
before it allows any State Police
19
officer to carry and administer
epinephrine delivery systems

20
epinephrine auto-injectors
.
21

(f) A physician, physician assistant with prescriptive
22
authority, or advanced practice registered nurse with
23
prescriptive authority may provide a standing protocol or
24
prescription for
epinephrine delivery systems

epinephrine
25
auto-injectors
in the name of the Illinois State Police to be
26
maintained for use when necessary.

HB3454 Enrolled
- 3 -
LRB104 09749 BDA 19815 b
1

(g) When a State Police officer administers an
epinephrine
2
delivery system

epinephrine auto-injector
in good faith, the
3
officer and the Illinois State Police, and its employees and
4
agents, including a physician, physician assistant with
5
prescriptive authority, or advanced practice registered nurse
6
with prescriptive authority who provides a standing order or
7
prescription for an
epinephrine delivery system

epinephrine
8
auto-injector
, incur no civil or professional liability,
9
except for willful and wanton conduct, as a result of any
10
injury or death arising from the use of an
epinephrine
11
delivery system

epinephrine auto-injector
.
12
(Source: P.A. 104-24, eff. 1-1-26
.)

13

Section 10.
The Illinois Police Training Act is amended by
14
changing Section 10.19 as follows:

15

(50 ILCS 705/10.19)
16

Sec. 10.19.
Training; administration of epinephrine.
17

(a) This Section, along with Section 40 of the Illinois
18
State Police Act, may be referred to as the Annie LeGere Law.
19

(b) For purposes of this Section,
"epinephrine delivery
20
system"

"epinephrine auto-injector"
means a single-use device
21
used for the automatic injection of a pre-measured dose of
22
epinephrine into the human body prescribed in the name of a
23
local law enforcement agency.
24

(c) The Board shall conduct or approve an optional

HB3454 Enrolled
- 4 -
LRB104 09749 BDA 19815 b
1
advanced training program for law enforcement officers to
2
recognize and respond to anaphylaxis, including the
3
administration of an
epinephrine delivery system

epinephrine
4
auto-injector
. The training must include, but is not limited
5
to:
6

(1) how to recognize symptoms of an allergic reaction;
7

(2) how to respond to an emergency involving an
8

allergic reaction;
9

(3) how to administer an
epinephrine delivery system

10

epinephrine auto-injector
;
11

(4) how to respond to an individual with a known
12

allergy as well as an individual with a previously unknown
13

allergy;
14

(5) a test demonstrating competency of the knowledge
15

required to recognize anaphylaxis and administer an
16

epinephrine delivery system

epinephrine auto-injector
; and
17

(6) other criteria as determined in rules adopted by
18

the Board.
19

(d) A local law enforcement agency may authorize a law
20
enforcement officer who has completed an optional advanced
21
training program under subsection (c) to carry, administer, or
22
assist with the administration of
epinephrine delivery systems

23
epinephrine auto-injectors
provided by the local law
24
enforcement agency whenever the officer is performing official
25
duties.
26

(e) A local law enforcement agency that authorizes its

HB3454 Enrolled
- 5 -
LRB104 09749 BDA 19815 b
1
officers to carry and administer
epinephrine delivery systems

2
epinephrine auto-injectors
under subsection (d) must establish
3
a policy to control the acquisition, storage, transportation,
4
administration, and disposal of
epinephrine delivery systems

5
epinephrine auto-injectors
and to provide continued training
6
in the administration of
epinephrine delivery systems

7
epinephrine auto-injectors
.
8

(f) A physician, physician assistant with prescriptive
9
authority, or advanced practice registered nurse with
10
prescriptive authority may provide a standing protocol or
11
prescription for
epinephrine delivery systems

epinephrine
12
auto-injectors
in the name of a local law enforcement agency
13
to be maintained for use when necessary.
14

(g) When a law enforcement officer administers an
15
epinephrine delivery system

epinephrine auto-injector
in good
16
faith, the law enforcement officer and local law enforcement
17
agency, and its employees and agents, including a physician,
18
physician assistant with prescriptive authority, or advanced
19
practice registered nurse with prescriptive authority who
20
provides a standing order or prescription for an
epinephrine
21
delivery system

epinephrine auto-injector
, incur no civil or
22
professional liability, except for willful and wanton conduct,
23
or as a result of any injury or death arising from the use of
24
an
epinephrine delivery system

epinephrine auto-injector
.
25
(Source: P.A. 102-538, eff. 8-20-21; 102-694, eff. 1-7-22;
26
103-154, eff. 6-30-23.)

HB3454 Enrolled
- 6 -
LRB104 09749 BDA 19815 b
1

Section 15.
The School Code is amended by changing Section
2
22-30 as follows:

3

(105 ILCS 5/22-30)
4

Sec. 22-30.
Self-administration and self-carry of asthma
5
medication and epinephrine
delivery systems

injectors
;
6
administration of undesignated epinephrine
delivery systems

7
injectors
; administration of an opioid antagonist;
8
administration of undesignated asthma medication; supply of
9
undesignated oxygen tanks; asthma episode emergency response
10
protocol.
11

(a) For the purpose of this Section only, the following
12
terms shall have the meanings set forth below:
13

"Asthma action plan" means a written plan developed with a
14
pupil's medical provider to help control the pupil's asthma.
15
The goal of an asthma action plan is to reduce or prevent
16
flare-ups and emergency department visits through day-to-day
17
management and to serve as a student-specific document to be
18
referenced in the event of an asthma episode.
19

"Asthma episode emergency response protocol" means a
20
procedure to provide assistance to a pupil experiencing
21
symptoms of wheezing, coughing, shortness of breath, chest
22
tightness, or breathing difficulty.
23

"Epinephrine
delivery system" means any form of
24
epinephrine that is approved by the United States Food and

HB3454 Enrolled
- 7 -
LRB104 09749 BDA 19815 b
1
Drug Administration, including any device that contains a dose
2
of epinephrine, and that is used to administer epinephrine
3
into the human body to prevent or treat a life-threatening
4
allergic reaction

injector" includes an auto-injector approved
5
by the United States Food and Drug Administration for the
6
administration of epinephrine and a pre-filled syringe
7
approved by the United States Food and Drug Administration and
8
used for the administration of epinephrine that contains a
9
pre-measured dose of epinephrine that is equivalent to the
10
dosages used in an auto-injector
.
11

"Asthma medication" means quick-relief asthma medication,
12
including albuterol or other short-acting bronchodilators,
13
that is approved by the United States Food and Drug
14
Administration for the treatment of respiratory distress.
15
"Asthma medication" includes medication delivered through a
16
device, including a metered dose inhaler with a reusable or
17
disposable spacer or a nebulizer with a mouthpiece or mask.
18

"Opioid antagonist" means a drug that binds to opioid
19
receptors and blocks or inhibits the effect of opioids acting
20
on those receptors, including, but not limited to, naloxone
21
hydrochloride or any other similarly acting drug approved by
22
the U.S. Food and Drug Administration.
23

"Respiratory distress" means the perceived or actual
24
presence of wheezing, coughing, shortness of breath, chest
25
tightness, breathing difficulty, or any other symptoms
26
consistent with asthma. Respiratory distress may be

HB3454 Enrolled
- 8 -
LRB104 09749 BDA 19815 b
1
categorized as "mild-to-moderate" or "severe".
2

"School nurse" means a registered nurse working in a
3
school with or without licensure endorsed in school nursing.
4

"Self-administration" means a pupil's discretionary use of
5
his or her prescribed asthma medication or epinephrine
6
delivery system

injector
.
7

"Self-carry" means a pupil's ability to carry his or her
8
prescribed asthma medication or epinephrine
delivery system

9
injector
.
10

"Standing protocol" may be issued by (i) a physician
11
licensed to practice medicine in all its branches, (ii) a
12
licensed physician assistant with prescriptive authority, or
13
(iii) a licensed advanced practice registered nurse with
14
prescriptive authority.
15

"Trained personnel" means any school employee or volunteer
16
personnel authorized in Sections 10-22.34, 10-22.34a, and
17
10-22.34b of this Code who has completed training under
18
subsection (g) of this Section to recognize and respond to
19
anaphylaxis, an opioid overdose, or respiratory distress.
20

"Undesignated asthma medication" means asthma medication
21
prescribed in the name of a school district, public school,
22
charter school, or nonpublic school.
23

"Undesignated epinephrine
delivery system

injector
" means
24
an epinephrine
delivery system

injector
prescribed in the name
25
of a school district, public school, charter school, or
26
nonpublic school.

HB3454 Enrolled
- 9 -
LRB104 09749 BDA 19815 b
1

(b) A school, whether public, charter, or nonpublic, must
2
permit the self-administration and self-carry of asthma
3
medication by a pupil with asthma or the self-administration
4
and self-carry of an epinephrine
delivery system

injector
by a
5
pupil, provided that:
6

(1) the parents or guardians of the pupil provide to
7

the school (i) written authorization from the parents or
8

guardians for (A) the self-administration and self-carry
9

of asthma medication or (B) the self-carry of asthma
10

medication or (ii) for (A) the self-administration and
11

self-carry of an epinephrine
delivery system

injector
or
12

(B) the self-carry of an epinephrine
delivery system

13

injector
, written authorization from the pupil's
14

physician, physician assistant, or advanced practice
15

registered nurse; and
16

(2) the parents or guardians of the pupil provide to
17

the school (i) the prescription label, which must contain
18

the name of the asthma medication, the prescribed dosage,
19

and the time at which or circumstances under which the
20

asthma medication is to be administered, or (ii) for the
21

self-administration or self-carry of an epinephrine
22

delivery system

injector
, a written statement from the
23

pupil's physician, physician assistant, or advanced
24

practice registered nurse containing the following
25

information:
26

(A) the name and purpose of the epinephrine

HB3454 Enrolled
- 10 -
LRB104 09749 BDA 19815 b
1

delivery system

injector
;
2

(B) the prescribed dosage; and
3

(C) the time or times at which or the special
4

circumstances under which the epinephrine
delivery
5

system

injector
is to be administered.
6
The information provided shall be kept on file in the office of
7
the school nurse or, in the absence of a school nurse, the
8
school's administrator.
9

(b-5) A school district, public school, charter school, or
10
nonpublic school may authorize the provision of a
11
student-specific or undesignated epinephrine
delivery system

12
injector
to a student or any personnel authorized under a
13
student's Individual Health Care Action Plan, allergy
14
emergency action plan, or plan pursuant to Section 504 of the
15
federal Rehabilitation Act of 1973 to administer an
16
epinephrine
delivery system

injector
to the student, that
17
meets the student's prescription on file.
18

(b-10) The school district, public school, charter school,
19
or nonpublic school may authorize a school nurse or trained
20
personnel to do the following: (i) provide an undesignated
21
epinephrine
delivery system

injector
to a student for
22
self-administration only or any personnel authorized under a
23
student's Individual Health Care Action Plan, allergy
24
emergency action plan, plan pursuant to Section 504 of the
25
federal Rehabilitation Act of 1973, or individualized
26
education program plan to administer to the student that meets

HB3454 Enrolled
- 11 -
LRB104 09749 BDA 19815 b
1
the student's prescription on file; (ii) administer an
2
undesignated epinephrine
delivery system

injector
that meets
3
the prescription on file to any student who has an Individual
4
Health Care Action Plan, allergy emergency action plan, plan
5
pursuant to Section 504 of the federal Rehabilitation Act of
6
1973, or individualized education program plan that authorizes
7
the use of an epinephrine
delivery system

injector
; (iii)
8
administer an undesignated epinephrine
delivery system

9
injector
to any person that the school nurse or trained
10
personnel in good faith believes is having an anaphylactic
11
reaction; (iv) administer an opioid antagonist to any person
12
that the school nurse or trained personnel in good faith
13
believes is having an opioid overdose; (v) provide
14
undesignated asthma medication to a student for
15
self-administration only or to any personnel authorized under
16
a student's Individual Health Care Action Plan or asthma
17
action plan, plan pursuant to Section 504 of the federal
18
Rehabilitation Act of 1973, or individualized education
19
program plan to administer to the student that meets the
20
student's prescription on file; (vi) administer undesignated
21
asthma medication that meets the prescription on file to any
22
student who has an Individual Health Care Action Plan or
23
asthma action plan, plan pursuant to Section 504 of the
24
federal Rehabilitation Act of 1973, or individualized
25
education program plan that authorizes the use of asthma
26
medication; and (vii) administer undesignated asthma

HB3454 Enrolled
- 12 -
LRB104 09749 BDA 19815 b
1
medication to any person that the school nurse or trained
2
personnel believes in good faith is having respiratory
3
distress.
4

(c) The school district, public school, charter school, or
5
nonpublic school must inform the parents or guardians of the
6
pupil, in writing, that the school district, public school,
7
charter school, or nonpublic school and its employees and
8
agents, including a physician, physician assistant, or
9
advanced practice registered nurse providing standing protocol
10
and a prescription for school epinephrine
delivery systems

11
injectors
, an opioid antagonist, or undesignated asthma
12
medication, are to incur no liability or professional
13
discipline, except for willful and wanton conduct, as a result
14
of any injury arising from the administration of asthma
15
medication, an epinephrine
delivery system

injector
, or an
16
opioid antagonist regardless of whether authorization was
17
given by the pupil's parents or guardians or by the pupil's
18
physician, physician assistant, or advanced practice
19
registered nurse. The parents or guardians of the pupil must
20
sign a statement acknowledging that the school district,
21
public school, charter school, or nonpublic school and its
22
employees and agents are to incur no liability, except for
23
willful and wanton conduct, as a result of any injury arising
24
from the administration of asthma medication, an epinephrine
25
delivery system

injector
, or an opioid antagonist regardless
26
of whether authorization was given by the pupil's parents or

HB3454 Enrolled
- 13 -
LRB104 09749 BDA 19815 b
1
guardians or by the pupil's physician, physician assistant, or
2
advanced practice registered nurse and that the parents or
3
guardians must indemnify and hold harmless the school
4
district, public school, charter school, or nonpublic school
5
and its employees and agents against any claims, except a
6
claim based on willful and wanton conduct, arising out of the
7
administration of asthma medication, an epinephrine
delivery
8
system

injector
, or an opioid antagonist regardless of whether
9
authorization was given by the pupil's parents or guardians or
10
by the pupil's physician, physician assistant, or advanced
11
practice registered nurse.
12

(c-5) When a school nurse or trained personnel administers
13
an undesignated epinephrine
delivery system

injector
to a
14
person whom the school nurse or trained personnel in good
15
faith believes is having an anaphylactic reaction, administers
16
an opioid antagonist to a person whom the school nurse or
17
trained personnel in good faith believes is having an opioid
18
overdose, or administers undesignated asthma medication to a
19
person whom the school nurse or trained personnel in good
20
faith believes is having respiratory distress, notwithstanding
21
the lack of notice to the parents or guardians of the pupil or
22
the absence of the parents or guardians signed statement
23
acknowledging no liability, except for willful and wanton
24
conduct, the school district, public school, charter school,
25
or nonpublic school and its employees and agents, and a
26
physician, a physician assistant, or an advanced practice

HB3454 Enrolled
- 14 -
LRB104 09749 BDA 19815 b
1
registered nurse providing standing protocol and a
2
prescription for undesignated epinephrine
delivery systems

3
injectors
, an opioid antagonist, or undesignated asthma
4
medication, are to incur no liability or professional
5
discipline, except for willful and wanton conduct, as a result
6
of any injury arising from the use of an undesignated
7
epinephrine
delivery system

injector
, the use of an opioid
8
antagonist, or the use of undesignated asthma medication,
9
regardless of whether authorization was given by the pupil's
10
parents or guardians or by the pupil's physician, physician
11
assistant, or advanced practice registered nurse.
12

(d) The permission for self-administration and self-carry
13
of asthma medication or the self-administration and self-carry
14
of an epinephrine
delivery system

injector
is effective for
15
the school year for which it is granted and shall be renewed
16
each subsequent school year upon fulfillment of the
17
requirements of this Section.
18

(e) Provided that the requirements of this Section are
19
fulfilled, a pupil with asthma may self-administer and
20
self-carry his or her asthma medication or a pupil may
21
self-administer and self-carry an epinephrine
delivery system

22
injector
(i) while in school, (ii) while at a school-sponsored
23
activity, (iii) while under the supervision of school
24
personnel, or (iv) before or after normal school activities,
25
such as while in before-school or after-school care on
26
school-operated property or while being transported on a

HB3454 Enrolled
- 15 -
LRB104 09749 BDA 19815 b
1
school bus.
2

(e-5) Provided that the requirements of this Section are
3
fulfilled, a school nurse or trained personnel may administer
4
an undesignated epinephrine
delivery system

injector
to any
5
person whom the school nurse or trained personnel in good
6
faith believes to be having an anaphylactic reaction (i) while
7
in school, (ii) while at a school-sponsored activity, (iii)
8
while under the supervision of school personnel, or (iv)
9
before or after normal school activities, such as while in
10
before-school or after-school care on school-operated property
11
or while being transported on a school bus. A school nurse or
12
trained personnel may carry undesignated epinephrine
delivery
13
systems

injectors
on his or her person while in school or at a
14
school-sponsored activity.
15

(e-10) Provided that the requirements of this Section are
16
fulfilled, a school nurse or trained personnel may administer
17
an opioid antagonist to any person whom the school nurse or
18
trained personnel in good faith believes to be having an
19
opioid overdose (i) while in school, (ii) while at a
20
school-sponsored activity, (iii) while under the supervision
21
of school personnel, or (iv) before or after normal school
22
activities, such as while in before-school or after-school
23
care on school-operated property. A school nurse or trained
24
personnel may carry an opioid antagonist on his or her person
25
while in school or at a school-sponsored activity.
26

(e-15) If the requirements of this Section are met, a

HB3454 Enrolled
- 16 -
LRB104 09749 BDA 19815 b
1
school nurse or trained personnel may administer undesignated
2
asthma medication to any person whom the school nurse or
3
trained personnel in good faith believes to be experiencing
4
respiratory distress (i) while in school, (ii) while at a
5
school-sponsored activity, (iii) while under the supervision
6
of school personnel, or (iv) before or after normal school
7
activities, including before-school or after-school care on
8
school-operated property. A school nurse or trained personnel
9
may carry undesignated asthma medication on his or her person
10
while in school or at a school-sponsored activity.
11

(f) The school district, public school, charter school, or
12
nonpublic school may maintain a supply of undesignated
13
epinephrine
delivery systems

injectors
in any secure location
14
that is accessible before, during, and after school where an
15
allergic person is most at risk, including, but not limited
16
to, classrooms and lunchrooms. A physician, a physician
17
assistant who has prescriptive authority in accordance with
18
Section 7.5 of the Physician Assistant Practice Act of 1987,
19
or an advanced practice registered nurse who has prescriptive
20
authority in accordance with Section 65-40 of the Nurse
21
Practice Act may prescribe undesignated epinephrine
delivery
22
systems

injectors
in the name of the school district, public
23
school, charter school, or nonpublic school to be maintained
24
for use when necessary. Any supply of epinephrine
delivery
25
systems

injectors
shall be maintained in accordance with the
26
manufacturer's instructions.

HB3454 Enrolled
- 17 -
LRB104 09749 BDA 19815 b
1

The school district, public school, charter school, or
2
nonpublic school shall maintain a supply of an opioid
3
antagonist in any secure location where an individual may have
4
an opioid overdose, unless there is a shortage of opioid
5
antagonists, in which case the school district, public school,
6
charter school, or nonpublic school shall make a reasonable
7
effort to maintain a supply of an opioid antagonist. Unless
8
the school district, public school, charter school, or
9
nonpublic school is able to obtain opioid antagonists without
10
a prescription, a health care professional who has been
11
delegated prescriptive authority for opioid antagonists in
12
accordance with Section 5-23 of the Substance Use Disorder Act
13
shall prescribe opioid antagonists in the name of the school
14
district, public school, charter school, or nonpublic school,
15
to be maintained for use when necessary. Any supply of opioid
16
antagonists shall be maintained in accordance with the
17
manufacturer's instructions.
18

The school district, public school, charter school, or
19
nonpublic school may maintain a supply of asthma medication in
20
any secure location that is accessible before, during, or
21
after school where a person is most at risk, including, but not
22
limited to, a classroom or the nurse's office. A physician, a
23
physician assistant who has prescriptive authority under
24
Section 7.5 of the Physician Assistant Practice Act of 1987,
25
or an advanced practice registered nurse who has prescriptive
26
authority under Section 65-40 of the Nurse Practice Act may

HB3454 Enrolled
- 18 -
LRB104 09749 BDA 19815 b
1
prescribe undesignated asthma medication in the name of the
2
school district, public school, charter school, or nonpublic
3
school to be maintained for use when necessary. Any supply of
4
undesignated asthma medication must be maintained in
5
accordance with the manufacturer's instructions.
6

A school district that provides special educational
7
facilities for children with disabilities under Section
8
14-4.01 of this Code may maintain a supply of undesignated
9
oxygen tanks in any secure location that is accessible before,
10
during, and after school where a person with developmental
11
disabilities is most at risk, including, but not limited to,
12
classrooms and lunchrooms. A physician, a physician assistant
13
who has prescriptive authority in accordance with Section 7.5
14
of the Physician Assistant Practice Act of 1987, or an
15
advanced practice registered nurse who has prescriptive
16
authority in accordance with Section 65-40 of the Nurse
17
Practice Act may prescribe undesignated oxygen tanks in the
18
name of the school district that provides special educational
19
facilities for children with disabilities under Section
20
14-4.01 of this Code to be maintained for use when necessary.
21
Any supply of oxygen tanks shall be maintained in accordance
22
with the manufacturer's instructions and with the local fire
23
department's rules.
24

(f-3) Whichever entity initiates the process of obtaining
25
undesignated epinephrine
delivery systems

injectors
and
26
providing training to personnel for carrying and administering

HB3454 Enrolled
- 19 -
LRB104 09749 BDA 19815 b
1
undesignated epinephrine
delivery systems

injectors
shall pay
2
for the costs of the undesignated epinephrine
delivery systems

3
injectors
.
4

(f-5) Upon any administration of an epinephrine
delivery
5
system

injector
, a school district, public school, charter
6
school, or nonpublic school must immediately activate the EMS
7
system and notify the student's parent, guardian, or emergency
8
contact, if known.
9

Upon any administration of an opioid antagonist, a school
10
district, public school, charter school, or nonpublic school
11
must immediately activate the EMS system and notify the
12
student's parent, guardian, or emergency contact, if known.
13

(f-10) Within 24 hours of the administration of an
14
undesignated epinephrine
delivery system

injector
, a school
15
district, public school, charter school, or nonpublic school
16
must notify the physician, physician assistant, or advanced
17
practice registered nurse who provided the standing protocol
18
and a prescription for the undesignated epinephrine
delivery
19
system

injector
of its use.
20

Within 24 hours after the administration of an opioid
21
antagonist, a school district, public school, charter school,
22
or nonpublic school must notify the health care professional
23
who provided the prescription for the opioid antagonist of its
24
use.
25

Within 24 hours after the administration of undesignated
26
asthma medication, a school district, public school, charter

HB3454 Enrolled
- 20 -
LRB104 09749 BDA 19815 b
1
school, or nonpublic school must notify the student's parent
2
or guardian or emergency contact, if known, and the physician,
3
physician assistant, or advanced practice registered nurse who
4
provided the standing protocol and a prescription for the
5
undesignated asthma medication of its use. The district or
6
school must follow up with the school nurse, if available, and
7
may, with the consent of the child's parent or guardian,
8
notify the child's health care provider of record, as
9
determined under this Section, of its use.
10

(g) Prior to the administration of an undesignated
11
epinephrine
delivery system

injector
, trained personnel must
12
submit to the school's administration proof of completion of a
13
training curriculum to recognize and respond to anaphylaxis
14
that meets the requirements of subsection (h) of this Section.
15
Training must be completed annually. The school district,
16
public school, charter school, or nonpublic school must
17
maintain records related to the training curriculum and
18
trained personnel.
19

Prior to the administration of an opioid antagonist,
20
trained personnel must submit to the school's administration
21
proof of completion of a training curriculum to recognize and
22
respond to an opioid overdose, which curriculum must meet the
23
requirements of subsection (h-5) of this Section. The school
24
district, public school, charter school, or nonpublic school
25
must maintain records relating to the training curriculum and
26
the trained personnel.

HB3454 Enrolled
- 21 -
LRB104 09749 BDA 19815 b
1

Prior to the administration of undesignated asthma
2
medication, trained personnel must submit to the school's
3
administration proof of completion of a training curriculum to
4
recognize and respond to respiratory distress, which must meet
5
the requirements of subsection (h-10) of this Section.
6
Training must be completed annually, and the school district,
7
public school, charter school, or nonpublic school must
8
maintain records relating to the training curriculum and the
9
trained personnel.
10

(h) A training curriculum to recognize and respond to
11
anaphylaxis, including the administration of an undesignated
12
epinephrine
delivery system

injector
, may be conducted online
13
or in person.
14

Training shall include, but is not limited to:
15

(1) how to recognize signs and symptoms of an allergic
16

reaction, including anaphylaxis;
17

(2) how to administer an epinephrine
delivery system

18

injector
; and
19

(3) a test demonstrating competency of the knowledge
20

required to recognize anaphylaxis and administer an
21

epinephrine
delivery system

injector
.
22

Training may also include, but is not limited to:
23

(A) a review of high-risk areas within a school and
24

its related facilities;
25

(B) steps to take to prevent exposure to allergens;
26

(C) emergency follow-up procedures, including the

HB3454 Enrolled
- 22 -
LRB104 09749 BDA 19815 b
1

importance of calling 9-1-1 or, if 9-1-1 is not available,
2

other local emergency medical services;
3

(D) how to respond to a student with a known allergy,
4

as well as a student with a previously unknown allergy;
5

(E) other criteria as determined in rules adopted
6

pursuant to this Section; and
7

(F) any policy developed by the State Board of
8

Education under Section 2-3.190.
9

In consultation with statewide professional organizations
10
representing physicians licensed to practice medicine in all
11
of its branches, registered nurses, and school nurses, the
12
State Board of Education shall make available resource
13
materials consistent with criteria in this subsection (h) for
14
educating trained personnel to recognize and respond to
15
anaphylaxis. The State Board may take into consideration the
16
curriculum on this subject developed by other states, as well
17
as any other curricular materials suggested by medical experts
18
and other groups that work on life-threatening allergy issues.
19
The State Board is not required to create new resource
20
materials. The State Board shall make these resource materials
21
available on its Internet website.
22

(h-5) A training curriculum to recognize and respond to an
23
opioid overdose, including the administration of an opioid
24
antagonist, may be conducted online or in person. The training
25
must comply with any training requirements under Section 5-23
26
of the Substance Use Disorder Act and the corresponding rules.

HB3454 Enrolled
- 23 -
LRB104 09749 BDA 19815 b
1
It must include, but is not limited to:
2

(1) how to recognize symptoms of an opioid overdose;
3

(2) information on drug overdose prevention and
4

recognition;
5

(3) how to perform rescue breathing and resuscitation;
6

(4) how to respond to an emergency involving an opioid
7

overdose;
8

(5) opioid antagonist dosage and administration;
9

(6) the importance of calling 9-1-1 or, if 9-1-1 is
10

not available, other local emergency medical services;
11

(7) care for the overdose victim after administration
12

of the overdose antagonist;
13

(8) a test demonstrating competency of the knowledge
14

required to recognize an opioid overdose and administer a
15

dose of an opioid antagonist; and
16

(9) other criteria as determined in rules adopted
17

pursuant to this Section.
18

(h-10) A training curriculum to recognize and respond to
19
respiratory distress, including the administration of
20
undesignated asthma medication, may be conducted online or in
21
person. The training must include, but is not limited to:
22

(1) how to recognize symptoms of respiratory distress
23

and how to distinguish respiratory distress from
24

anaphylaxis;
25

(2) how to respond to an emergency involving
26

respiratory distress;

HB3454 Enrolled
- 24 -
LRB104 09749 BDA 19815 b
1

(3) asthma medication dosage and administration;
2

(4) the importance of calling 9-1-1 or, if 9-1-1 is
3

not available, other local emergency medical services;
4

(5) a test demonstrating competency of the knowledge
5

required to recognize respiratory distress and administer
6

asthma medication; and
7

(6) other criteria as determined in rules adopted
8

under this Section.
9

(i) Within 3 days after the administration of an
10
undesignated epinephrine
delivery system

injector
by a school
11
nurse, trained personnel, or a student at a school or
12
school-sponsored activity, the school must report to the State
13
Board of Education in a form and manner prescribed by the State
14
Board the following information:
15

(1) age and type of person receiving epinephrine
16

(student, staff, visitor);
17

(2) any previously known diagnosis of a severe
18

allergy;
19

(3) trigger that precipitated allergic episode;
20

(4) location where symptoms developed;
21

(5) number of doses administered;
22

(6) type of person administering epinephrine (school
23

nurse, trained personnel, student); and
24

(7) any other information required by the State Board.
25

If a school district, public school, charter school, or
26
nonpublic school maintains or has an independent contractor

HB3454 Enrolled
- 25 -
LRB104 09749 BDA 19815 b
1
providing transportation to students who maintains a supply of
2
undesignated epinephrine
delivery systems

injectors
, then the
3
school district, public school, charter school, or nonpublic
4
school must report that information to the State Board of
5
Education upon adoption or change of the policy of the school
6
district, public school, charter school, nonpublic school, or
7
independent contractor, in a manner as prescribed by the State
8
Board. The report must include the number of undesignated
9
epinephrine
delivery systems

injectors
in supply.
10

(i-5) Within 3 days after the administration of an opioid
11
antagonist by a school nurse or trained personnel, the school
12
must report to the State Board of Education, in a form and
13
manner prescribed by the State Board, the following
14
information:
15

(1) the age and type of person receiving the opioid
16

antagonist (student, staff, or visitor);
17

(2) the location where symptoms developed;
18

(3) the type of person administering the opioid
19

antagonist (school nurse or trained personnel); and
20

(4) any other information required by the State Board.
21

(i-10) Within 3 days after the administration of
22
undesignated asthma medication by a school nurse, trained
23
personnel, or a student at a school or school-sponsored
24
activity, the school must report to the State Board of
25
Education, on a form and in a manner prescribed by the State
26
Board of Education, the following information:

HB3454 Enrolled
- 26 -
LRB104 09749 BDA 19815 b
1

(1) the age and type of person receiving the asthma
2

medication (student, staff, or visitor);
3

(2) any previously known diagnosis of asthma for the
4

person;
5

(3) the trigger that precipitated respiratory
6

distress, if identifiable;
7

(4) the location of where the symptoms developed;
8

(5) the number of doses administered;
9

(6) the type of person administering the asthma
10

medication (school nurse, trained personnel, or student);
11

(7) the outcome of the asthma medication
12

administration; and
13

(8) any other information required by the State Board.
14

(j) By October 1, 2015 and every year thereafter, the
15
State Board of Education shall submit a report to the General
16
Assembly identifying the frequency and circumstances of
17
undesignated epinephrine and undesignated asthma medication
18
administration during the preceding academic year. Beginning
19
with the 2017 report, the report shall also contain
20
information on which school districts, public schools, charter
21
schools, and nonpublic schools maintain or have independent
22
contractors providing transportation to students who maintain
23
a supply of undesignated epinephrine
delivery systems

24
injectors
. This report shall be published on the State Board's
25
Internet website on the date the report is delivered to the
26
General Assembly.

HB3454 Enrolled
- 27 -
LRB104 09749 BDA 19815 b
1

(j-5) Annually, each school district, public school,
2
charter school, or nonpublic school shall request an asthma
3
action plan from the parents or guardians of a pupil with
4
asthma. If provided, the asthma action plan must be kept on
5
file in the office of the school nurse or, in the absence of a
6
school nurse, the school administrator. Copies of the asthma
7
action plan may be distributed to appropriate school staff who
8
interact with the pupil on a regular basis, and, if
9
applicable, may be attached to the pupil's federal Section 504
10
plan or individualized education program plan.
11

(j-10) To assist schools with emergency response
12
procedures for asthma, the State Board of Education, in
13
consultation with statewide professional organizations with
14
expertise in asthma management and a statewide organization
15
representing school administrators, shall develop a model
16
asthma episode emergency response protocol before September 1,
17
2016. Each school district, charter school, and nonpublic
18
school shall adopt an asthma episode emergency response
19
protocol before January 1, 2017 that includes all of the
20
components of the State Board's model protocol.
21

(j-15) (Blank).
22

(j-20) On or before October 1, 2016 and every year
23
thereafter, the State Board of Education shall submit a report
24
to the General Assembly and the Department of Public Health
25
identifying the frequency and circumstances of opioid
26
antagonist administration during the preceding academic year.

HB3454 Enrolled
- 28 -
LRB104 09749 BDA 19815 b
1
This report shall be published on the State Board's Internet
2
website on the date the report is delivered to the General
3
Assembly.
4

(k) The State Board of Education may adopt rules necessary
5
to implement this Section.
6

(l) Nothing in this Section shall limit the amount of
7
epinephrine
delivery systems

injectors
that any type of school
8
or student may carry or maintain a supply of.
9
(Source: P.A. 102-413, eff. 8-20-21; 102-813, eff. 5-13-22;
10
103-175, eff. 6-30-23; 103-196, eff. 1-1-24; 103-348, eff.
11
1-1-24; 103-542, eff. 7-1-24 (see Section 905 of P.A. 103-563
12
for effective date of P.A. 103-542); 103-605, eff. 7-1-24.)

13

Section 20.
The Illinois Insurance Code is amended by
14
changing Section 356z.33 as follows:

15

(215 ILCS 5/356z.33)
16

Sec. 356z.33.
Coverage for
epinephrine delivery systems

17
epinephrine injectors
.
18

(a) A group or individual policy of accident and health
19
insurance or a managed care plan that is amended, delivered,
20
issued, or renewed on or after January 1, 2020 (the effective
21
date of Public Act 101-281) shall provide coverage for
22
medically necessary
epinephrine delivery systems

epinephrine
23
injectors
for persons 18 years of age or under. As used in this
24
Section,
"epinephrine delivery system"

"epinephrine injector"

HB3454 Enrolled
- 29 -
LRB104 09749 BDA 19815 b
1
has the meaning given to that term in Section 5 of the
2
Epinephrine Delivery System

Epinephrine Injector
Act.
3

(b) An insurer that provides coverage for medically
4
necessary
epinephrine delivery systems

epinephrine injectors

5
shall limit the total amount that an insured is required to pay
6
for a twin-pack of medically necessary
epinephrine delivery
7
systems

epinephrine injectors
at an amount not to exceed $60,
8
regardless of the type of
epinephrine delivery system

9
epinephrine injector
; except that this provision does not
10
apply to the extent such coverage would disqualify a
11
high-deductible health plan from eligibility for a health
12
savings account pursuant to Section 223 of the Internal
13
Revenue Code (26 U.S.C. 223).
14

(c) Nothing in this Section prevents an insurer from
15
reducing an insured's cost sharing by an amount greater than
16
the amount specified in subsection (b).
17

(d) The Department may adopt rules as necessary to
18
implement and administer this Section.
19
(Source: P.A. 102-558, eff. 8-20-21; 103-454, eff. 1-1-25;
20
103-718, eff. 7-19-24
.)

21

Section 25.
The Medical Practice Act of 1987 is amended by
22
changing Section 65 as follows:

23

(225 ILCS 60/65)
24

(Section scheduled to be repealed on January 1, 2027)

HB3454 Enrolled
- 30 -
LRB104 09749 BDA 19815 b
1

Sec. 65.
Annie LeGere Law;
epinephrine delivery system

2
epinephrine auto-injector
.
A licensee under this Act may not
3
be subject to discipline for providing a standing order or
4
prescription for an
epinephrine delivery system

epinephrine
5
auto-injector
in accordance with Section 40 of the Illinois
6
State Police Act or Section 10.19 of the Illinois Police
7
Training Act.
8
(Source: P.A. 102-538, eff. 8-20-21.)

9

Section 30.
The Epinephrine Injector Act is amended by
10
changing Sections 1, 5, 10, 15, and 20 as follows:

11

(410 ILCS 27/1)
12

Sec. 1.
Short title.
This Act may be cited as the
13
Epinephrine Delivery System

Epinephrine Injector
Act.
14
(Source: P.A. 99-711, eff. 1-1-17; 100-799, eff. 1-1-19
.)

15

(410 ILCS 27/5)
16

Sec. 5.
Definitions.
As used in this Act:
17

"Administer" means to directly apply an epinephrine
18
delivery system to the body of an individual.
19

"Authorized entity" means any entity or organization,
20
other than a school covered under Section 22-30 of the School
21
Code, in connection with or at which allergens capable of
22
causing anaphylaxis may be present, including, but not limited
23
to, independent contractors who provide student transportation

HB3454 Enrolled
- 31 -
LRB104 09749 BDA 19815 b
1
to schools, recreation camps, colleges and universities, day
2
care facilities, youth sports leagues, amusement parks,
3
restaurants, sports arenas, and places of employment. The
4
Department shall, by rule, determine what constitutes a day
5
care facility under this definition.
6

"Authorized individual" means an individual who has
7
successfully completed the training program under Section 10
8
of this Act.
9

"Department" means the Department of Public Health.
10

"Epinephrine delivery system" means any form of
11
epinephrine that is approved by the United States Food and
12
Drug Administration, including any device that contains a dose
13
of epinephrine, and that is used to administer epinephrine
14
into the human body to prevent or treat a life-threatening
15
allergic reaction.
16

"Health care practitioner" means a physician licensed to
17
practice medicine in all its branches under the Medical
18
Practice Act of 1987, a physician assistant under the
19
Physician Assistant Practice Act of 1987 with prescriptive
20
authority, or an advanced practice registered nurse with
21
prescribing authority under Article 65 of the Nurse Practice
22
Act.
23

"Pharmacist" has the meaning given to that term under
24
subsection (k-5) of Section 3 of the Pharmacy Practice Act.
25

"Undesignated epinephrine
delivery system

injector
" means
26
an epinephrine
delivery system

injector
prescribed in the name

HB3454 Enrolled
- 32 -
LRB104 09749 BDA 19815 b
1
of an authorized entity.
2
(Source: P.A. 104-229, eff. 1-1-26
.)

3

(410 ILCS 27/10)
4

Sec. 10.
Prescription to authorized entity; use; training.
5

(a) A health care practitioner may prescribe epinephrine
6
delivery systems

injectors
in the name of an authorized entity
7
or authorized individual for use in accordance with this Act,
8
and pharmacists and health care practitioners may dispense
9
epinephrine delivery systems pursuant to a prescription issued
10
in the name of an authorized entity or authorized individual.
11
Such prescriptions shall be valid for a period of 2 years.
12

(a-1) A health care provider with prescribing authority
13
who is employed by or under contract with the Department may
14
issue a statewide standing order for the dispensing of
15
epinephrine delivery systems for use under subsection (c) by
16
authorized individuals or by employees or agents of authorized
17
entities who have completed the training required by
18
subsection (d).
19

(b) An authorized entity or authorized individual may
20
acquire and stock a supply of undesignated epinephrine
21
delivery systems pursuant to a prescription issued under
22
subsection (a) of this Section. Such undesignated epinephrine
23
delivery systems shall be stored in a location readily
24
accessible in an emergency and in accordance with the
25
instructions for use of the epinephrine delivery systems. The

HB3454 Enrolled
- 33 -
LRB104 09749 BDA 19815 b
1
Department may establish any additional requirements an
2
authorized entity or authorized individual must follow under
3
this Act.
4

(c) An employee or agent of an authorized entity who is an
5
authorized individual or any other individual who is an
6
authorized individual may:
7

(1) anywhere allergens capable of causing anaphylaxis
8

may be present provide an epinephrine delivery system to
9

any individual whom the employee, agent, or other
10

individual believes in good faith is experiencing
11

anaphylaxis, or to the parent, guardian, or caregiver of
12

such individual, for immediate administration, regardless
13

of whether the individual has a prescription for an
14

epinephrine delivery system or has previously been
15

diagnosed with an allergy; or
16

(2) anywhere allergens capable of causing anaphylaxis
17

may be present administer an epinephrine delivery system
18

to any individual whom the employee, agent, or other
19

individual believes in good faith is experiencing
20

anaphylaxis, regardless of whether the individual has a
21

prescription for an epinephrine delivery system or has
22

previously been diagnosed with an allergy.
23

(d) An employee, agent, or other individual authorized
24
must complete an anaphylaxis training program before he or she
25
is able to provide or administer an epinephrine delivery
26
system under this Section. Such training shall be valid for a

HB3454 Enrolled
- 34 -
LRB104 09749 BDA 19815 b
1
period of 2 years and shall be conducted by a nationally
2
recognized organization experienced in training laypersons in
3
emergency health treatment. The Department shall include links
4
to training providers' websites on its website.
5

Training shall include, but is not limited to:
6

(1) how to recognize signs and symptoms of an allergic
7

reaction, including anaphylaxis;
8

(2) how to administer an epinephrine delivery system;
9

and
10

(3) a test demonstrating competency of the knowledge
11

required to recognize anaphylaxis and administer an
12

epinephrine delivery system.
13

Training may also include, but is not limited to:
14

(A) a review of high-risk areas on the authorized
15

entity's property and its related facilities;
16

(B) steps to take to prevent exposure to allergens;
17

(C) emergency follow-up procedures; and
18

(D) other criteria as determined in rules adopted
19

pursuant to this Act.
20

Training may be conducted either online or in person. The
21
entity or individual conducting the training shall issue a
22
certificate to each person who successfully completes the
23
anaphylaxis training program. The Department shall approve
24
training programs and list permitted training programs on the
25
Department's Internet website.
26
(Source: P.A. 104-229, eff. 1-1-26
.)

HB3454 Enrolled
- 35 -
LRB104 09749 BDA 19815 b
1

(410 ILCS 27/15)
2

Sec. 15.
Costs.
Whichever entity initiates the process of
3
obtaining undesignated epinephrine delivery systems and
4
providing training to personnel for carrying and administering
5
undesignated epinephrine delivery systems shall pay for the
6
costs of the undesignated epinephrine delivery systems.
7
(Source: P.A. 104-229, eff. 1-1-26
.)

8

(410 ILCS 27/20)
9

Sec. 20.
Limitations.
The use of an undesignated
10
epinephrine delivery system in accordance with the
11
requirements of this Act does not constitute the practice of
12
medicine or any other profession that requires medical
13
licensure.
14

Nothing in this Act shall limit the amount of epinephrine
15
delivery systems that an authorized entity or individual may
16
carry or maintain a supply of.
17
(Source: P.A. 104-229, eff. 1-1-26
.)

18

Section 35.
The Emergency Asthma Inhalers and Allergy
19
Treatment for Children Act is amended by changing Section 10
20
as follows:

21

(410 ILCS 607/10)
22

Sec. 10.
Possession, self-administration, and use of

HB3454 Enrolled
- 36 -
LRB104 09749 BDA 19815 b
1
epinephrine delivery systems

epinephrine auto-injectors
or
2
inhalers at recreation camps and after-school care programs.
3

(a) A recreation camp or an after-school care program
4
shall permit a child with severe, potentially life-threatening
5
allergies to possess, self-administer, and use an
epinephrine
6
delivery system

epinephrine auto-injector
or inhaler, if the
7
following conditions are satisfied:
8

(1) The child has the written approval of his or her
9

parent or guardian.
10

(2) The recreational camp or after-school care program
11

administrator or, if a nurse is assigned to the camp or
12

program, the nurse shall receive copies of the written
13

approvals required under paragraph (1) of subsection (a)
14

of this Section.
15

(3) The child's parent or guardian shall submit
16

written verification confirming that the child has the
17

knowledge and skills to safely possess, self-administer,
18

and use an
epinephrine delivery system

epinephrine
19

auto-injector
or inhaler in a camp or an after-school care
20

program setting.
21

(b) The child's parent or guardian shall provide the camp
22
or program with the following information:
23

(1) the child's name;
24

(2) the name, route, and dosage of medication;
25

(3) the frequency and time of medication
26

administration or assistance;

HB3454 Enrolled
- 37 -
LRB104 09749 BDA 19815 b
1

(4) the date of the order;
2

(5) a diagnosis and any other medical conditions
3

requiring medications, if not a violation of
4

confidentiality or if not contrary to the request of the
5

parent or guardian to keep confidential;
6

(6) specific recommendations for administration;
7

(7) any special side effects, contraindications, and
8

adverse reactions to be observed;
9

(8) the name of each required medication; and
10

(9) any severe adverse reactions that may occur to
11

another child, for whom the
epinephrine delivery system

12

epinephrine auto-injector
or inhaler is not prescribed,
13

should the other child receive a dose of the medication.
14

(c) If the conditions of this Act are satisfied, the child
15
may possess, self-administer, and use an
epinephrine delivery
16
system

epinephrine auto-injector
or inhaler at the camp or
17
after-school care program or at any camp-sponsored or
18
program-sponsored activity, event, or program.
19

(d) The recreational camp or after-school care program
20
must inform the parents or guardians of the child, in writing,
21
that the recreational camp or after-school care program and
22
its employees and agents are to incur no liability, as
23
applicable, except for willful and wanton conduct, as a result
24
of any injury arising from the self-administration of
25
medication to the child. The parents or guardians of the child
26
must sign a statement acknowledging that the recreational camp

HB3454 Enrolled
- 38 -
LRB104 09749 BDA 19815 b
1
or after-school care program is to incur no liability, except
2
for willful and wanton conduct, as a result of any injury
3
arising from the self-administration of medication by the
4
child and that the parents or guardians must indemnify and
5
hold harmless the recreational camp or after-school care
6
program and its employees and agents, as applicable, against
7
any claims, except a claim based on willful and wanton
8
conduct, arising out of the self-administration of medication
9
by the child.
10

(e) After-school care program personnel who have completed
11
an anaphylaxis training program as identified under the
12
Epinephrine Delivery System

Epinephrine Injector
Act may
13
administer an undesignated epinephrine injection to any child
14
if the after-school care program personnel believe in good
15
faith that the child is having an anaphylactic reaction while
16
in the after-school care program. After-school care program
17
personnel may carry undesignated
epinephrine delivery systems

18
epinephrine injectors
on their person while in the
19
after-school care program.
20

(f) After-school care program personnel may administer
21
undesignated asthma medication to any child if the
22
after-school care program personnel believe in good faith that
23
the child is experiencing respiratory distress while in the
24
after-school care program. After-school care program personnel
25
may carry undesignated asthma medication on their person while
26
in the after-school care program.

HB3454 Enrolled
- 39 -
LRB104 09749 BDA 19815 b
1

(g) If after-school care program personnel are to
2
administer an undesignated epinephrine injection or an
3
undesignated asthma medication to a child, the after-school
4
care program personnel must inform the parents or guardians of
5
the child, in writing, that the after-school care program and
6
its employees and agents, acting in accordance with standard
7
protocols and the prescription for the injection or
8
medication, shall incur no liability, except for willful and
9
wanton conduct, as a result of any injury arising from the
10
administration of the injection or medication, notwithstanding
11
whether authorization was given by the child's parents or
12
guardians or by the child's physician, physician assistant, or
13
advanced practice registered nurse. A parent or guardian of
14
the child must sign a statement acknowledging that the
15
after-school care program and its employees and agents are to
16
incur no liability, except for willful and wanton conduct, as
17
a result of any injury arising from the administration of the
18
medication or injection, regardless of whether authorization
19
was given by a parent or guardian of the child or by the
20
child's physician, physician assistant, or advanced practice
21
registered nurse, and that the parent or guardian must also
22
indemnify and hold harmless the after-school care program and
23
its employees and agents against any claims, except a claim
24
based on willful and wanton conduct, arising out of the
25
administration of the medication or injection, regardless of
26
whether authorization was given by the child's parent or

HB3454 Enrolled
- 40 -
LRB104 09749 BDA 19815 b
1
guardian or by the child's physician, physician assistant, or
2
advanced practice registered nurse.
3

(h) If after-school care program personnel administer an
4
undesignated epinephrine injection to a person and the
5
after-school care program personnel believe in good faith the
6
person is having an anaphylactic reaction or administer
7
undesignated asthma medication to a person and believe in good
8
faith the person is experiencing respiratory distress, then
9
the after-school care program and its employees and agents,
10
acting in accordance with standard protocols and the
11
prescription for the injection or medication, shall not incur
12
any liability or be subject to professional discipline, except
13
for willful and wanton conduct, as a result of any injury
14
arising from the use of the injection or medication,
15
notwithstanding whether notice was given to or authorization
16
was given by the child's parent or guardian or by the child's
17
physician, physician assistant, or advanced practice
18
registered nurse and notwithstanding the absence of the
19
parent's or guardian's signed statement acknowledging release
20
from liability.
21

(i) The changes made to this Section by this amendatory
22
Act of the 103rd General Assembly apply to actions filed on or
23
after the effective date of this amendatory Act of the 103rd
24
General Assembly.
25
(Source: P.A. 103-438, eff. 8-4-23.)

HB3454 Enrolled
- 41 -
LRB104 09749 BDA 19815 b
1

Section 40.
The Illinois Food, Drug and Cosmetic Act is
2
amended by changing Section 3.21 as follows:

3

(410 ILCS 620/3.21)

(from Ch. 56 1/2, par. 503.21)
4

Sec. 3.21.
Except as authorized by this Act, the Illinois
5
Controlled Substances Act, the Pharmacy Practice Act, the
6
Dental Practice Act, the Medical Practice Act of 1987, the
7
Veterinary Medicine and Surgery Practice Act of 2004, the
8
Podiatric Medical Practice Act of 1987, Section 22-30 of the
9
School Code, Section 40 of the Illinois State Police Act,
10
Section 10.19 of the Illinois Police Training Act, or the
11
Epinephrine Delivery System

Epinephrine Injector
Act, to sell
12
or dispense a prescription drug without a prescription.
13
(Source: P.A. 102-538, eff. 8-20-21.)

Footer

Disclaimer

This site is maintained for the Illinois General Assembly by the
Legislative Information System, 705 Stratton Building, Springfield, Illinois 62706.

Contact ILGA Webmaster

ILGA.gov uses cookies to ensure you get the best experience on our website. By continuing to browse ILGA.gov you consent to our use of cookies.
Read About Cookies

ILGA.GOV

2026 ILGA.gov | All Rights Reserved |
ADA

|
Disclaimers
|
Learn

This site is maintained for the Illinois General Assembly by the
Legislative Information System, 705 Stratton Building, Springfield, Illinois 62706.
Contact ILGA Webmaster

ILGA.gov uses cookies to ensure you get the best experience on our website. By continuing to browse ILGA.gov you consent to our use of cookies.
Read About Cookies

ILGA.GOV

2026 ILGA.gov | All Rights Reserved |
ADA

|
Disclaimers
|
Learn